Trial
NCT01141478
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Loma Linda University
Collaborators
—
Condition
Carcinoma, Hepatocellular
Intervention
Proton Beam Radiotherapy
Why stopped
due to low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-15